dna microarray (Thermo Fisher)
Thermo Fisher is a verified supplier 
Thermo Fisher manufactures this product 
99
Structured Review
Thermo Fisher
dna microarray
Dna Microarray, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dna+microarray/DNA/us12605397-375-148-161
Average 99 stars, based on 1 article reviews
Dna Microarray, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dna+microarray/DNA/us12605397-375-148-161
Average 99 stars, based on 1 article reviews
dna microarray - by Bioz Stars,
2026-09
99/100 stars
Images
Related Articles
Hybridization:Article Title: Integrative Radiogenomics Using MRI Radiomics and Microarray Gene Expression Analysis to Predict Pathological Complete Response in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy Article Snippet: The amplified cDNA was then biotinylated, fragmented using the FL-Ovation cDNA Biotin Module V2 (NuGEN), and hybridized to the Affymetrix GeneChip Human Genome U133 Plus 2.0 Array (Affymetrix) overnight (17 h) according to the manufacturer’s protocol. .. After hybridization, the Microarray:Article Title: Integrative Radiogenomics Using MRI Radiomics and Microarray Gene Expression Analysis to Predict Pathological Complete Response in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy Article Snippet: The amplified cDNA was then biotinylated, fragmented using the FL-Ovation cDNA Biotin Module V2 (NuGEN), and hybridized to the Affymetrix GeneChip Human Genome U133 Plus 2.0 Array (Affymetrix) overnight (17 h) according to the manufacturer’s protocol. .. After hybridization, the Article Title: Microfluidic reaction vessel array with patterned films Article Snippet: .. Early biochips were based on the idea of a Article Title: Adaptive individualized gene pair signatures distinguishing melanoma and predicting response to immune checkpoint blockade Article Snippet: .. The gene chips used in the Article Title: The transcription factor ZFP64 promotes activity-dependent synapse elimination during postnatal cerebellar development Article Snippet: .. Total RNA was extracted from the isolated PCs of L7-GFP mice by FACS and used as a template in the GeneChip Mouse Genome 430 2.0 Article Title: Charcot–Marie–Tooth-like presentation in giant axonal neuropathy: clinical variability and prevalence in a large Japanese case series Article Snippet: For all analyses, genomic DNA was extracted from peripheral blood using a Puregene Core Kit C (QIAGEN, Hilden, Germany) following the manufacturer’s instructions. .. Between 2007 and 2012, we performed genetic screening in 417 patients using Article Title: Reconsidering the definition of triple-negative breast cancer in the immune checkpoint inhibitor era: an optimal cut-off value for hormone receptor percentage of HER2-negative invasive breast cancer Article Snippet: .. Biologically, Iwamoto et al. analyzed RNA expression measured by Article Title: Deoxy-cytidine or uridine derivatives for use in cancer therapies Article Snippet: .. Microarray Method A comprises the following steps: 1) Extracting RNA from cancer/tumour cells of interest, said extraction preferably being performed using a Norgen Total RNA Purification kit (Norgen Biotek Cat nr. 17200); 2) Preparing Poly(A)+ RNA from the extracted RNA, preferably using a MEGApure kit according to the manufacturer's instructions (Ambion); 3) Preparing complementary DNA (cDNA) from the Poly(A)+ RNA by treatment with reverse transcriptase, i.e. performing reverse transcription; 4) Fragmenting the cDNA using TdT (terminal deoxynucleotidyl transferase); 5) Biotinylating the cDNA fragments using the GeneChip WT Terminal labelling kit (Affymetrix); 6 Repeating steps 1 to 5 with a reference cell line, wherein said reference cell line is MDA-MB-231; 7) Hybridizing 5.5 μg of the biotinylated cDNA fragments obtained in step 5 to a Article Title: Integrative Radiogenomics Using MRI Radiomics and Microarray Gene Expression Analysis to Predict Pathological Complete Response in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy Article Snippet: .. Microarray features As described in previous studies , RNA was extracted using TRIzol (Invitrogen, USA) from core-needle tumor biopsy samples obtained using the Mammotome (Mammotome 8G; HH Ethicon Endosurgery/Johnson and Johnson Company, USA) and analyzed using a Staining:Article Title: Integrative Radiogenomics Using MRI Radiomics and Microarray Gene Expression Analysis to Predict Pathological Complete Response in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy Article Snippet: The amplified cDNA was then biotinylated, fragmented using the FL-Ovation cDNA Biotin Module V2 (NuGEN), and hybridized to the Affymetrix GeneChip Human Genome U133 Plus 2.0 Array (Affymetrix) overnight (17 h) according to the manufacturer’s protocol. .. After hybridization, the Article Title: Deoxy-cytidine or uridine derivatives for use in cancer therapies Article Snippet: .. Microarray Method A comprises the following steps: 1) Extracting RNA from cancer/tumour cells of interest, said extraction preferably being performed using a Norgen Total RNA Purification kit (Norgen Biotek Cat nr. 17200); 2) Preparing Poly(A)+ RNA from the extracted RNA, preferably using a MEGApure kit according to the manufacturer's instructions (Ambion); 3) Preparing complementary DNA (cDNA) from the Poly(A)+ RNA by treatment with reverse transcriptase, i.e. performing reverse transcription; 4) Fragmenting the cDNA using TdT (terminal deoxynucleotidyl transferase); 5) Biotinylating the cDNA fragments using the GeneChip WT Terminal labelling kit (Affymetrix); 6 Repeating steps 1 to 5 with a reference cell line, wherein said reference cell line is MDA-MB-231; 7) Hybridizing 5.5 μg of the biotinylated cDNA fragments obtained in step 5 to a Fluorescence:Article Title: Integrative Radiogenomics Using MRI Radiomics and Microarray Gene Expression Analysis to Predict Pathological Complete Response in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy Article Snippet: The amplified cDNA was then biotinylated, fragmented using the FL-Ovation cDNA Biotin Module V2 (NuGEN), and hybridized to the Affymetrix GeneChip Human Genome U133 Plus 2.0 Array (Affymetrix) overnight (17 h) according to the manufacturer’s protocol. .. After hybridization, the DNA Array:Article Title: Microfluidic reaction vessel array with patterned films Article Snippet: .. Early biochips were based on the idea of a Isolation:Article Title: The transcription factor ZFP64 promotes activity-dependent synapse elimination during postnatal cerebellar development Article Snippet: .. Total RNA was extracted from the isolated PCs of L7-GFP mice by FACS and used as a template in the GeneChip Mouse Genome 430 2.0 FACS:Article Title: The transcription factor ZFP64 promotes activity-dependent synapse elimination during postnatal cerebellar development Article Snippet: .. Total RNA was extracted from the isolated PCs of L7-GFP mice by FACS and used as a template in the GeneChip Mouse Genome 430 2.0 RNA Expression:Article Title: Reconsidering the definition of triple-negative breast cancer in the immune checkpoint inhibitor era: an optimal cut-off value for hormone receptor percentage of HER2-negative invasive breast cancer Article Snippet: .. Biologically, Iwamoto et al. analyzed RNA expression measured by Extraction:Article Title: Deoxy-cytidine or uridine derivatives for use in cancer therapies Article Snippet: .. Microarray Method A comprises the following steps: 1) Extracting RNA from cancer/tumour cells of interest, said extraction preferably being performed using a Norgen Total RNA Purification kit (Norgen Biotek Cat nr. 17200); 2) Preparing Poly(A)+ RNA from the extracted RNA, preferably using a MEGApure kit according to the manufacturer's instructions (Ambion); 3) Preparing complementary DNA (cDNA) from the Poly(A)+ RNA by treatment with reverse transcriptase, i.e. performing reverse transcription; 4) Fragmenting the cDNA using TdT (terminal deoxynucleotidyl transferase); 5) Biotinylating the cDNA fragments using the GeneChip WT Terminal labelling kit (Affymetrix); 6 Repeating steps 1 to 5 with a reference cell line, wherein said reference cell line is MDA-MB-231; 7) Hybridizing 5.5 μg of the biotinylated cDNA fragments obtained in step 5 to a Purification:Article Title: Deoxy-cytidine or uridine derivatives for use in cancer therapies Article Snippet: .. Microarray Method A comprises the following steps: 1) Extracting RNA from cancer/tumour cells of interest, said extraction preferably being performed using a Norgen Total RNA Purification kit (Norgen Biotek Cat nr. 17200); 2) Preparing Poly(A)+ RNA from the extracted RNA, preferably using a MEGApure kit according to the manufacturer's instructions (Ambion); 3) Preparing complementary DNA (cDNA) from the Poly(A)+ RNA by treatment with reverse transcriptase, i.e. performing reverse transcription; 4) Fragmenting the cDNA using TdT (terminal deoxynucleotidyl transferase); 5) Biotinylating the cDNA fragments using the GeneChip WT Terminal labelling kit (Affymetrix); 6 Repeating steps 1 to 5 with a reference cell line, wherein said reference cell line is MDA-MB-231; 7) Hybridizing 5.5 μg of the biotinylated cDNA fragments obtained in step 5 to a Reverse Transcription:Article Title: Deoxy-cytidine or uridine derivatives for use in cancer therapies Article Snippet: .. Microarray Method A comprises the following steps: 1) Extracting RNA from cancer/tumour cells of interest, said extraction preferably being performed using a Norgen Total RNA Purification kit (Norgen Biotek Cat nr. 17200); 2) Preparing Poly(A)+ RNA from the extracted RNA, preferably using a MEGApure kit according to the manufacturer's instructions (Ambion); 3) Preparing complementary DNA (cDNA) from the Poly(A)+ RNA by treatment with reverse transcriptase, i.e. performing reverse transcription; 4) Fragmenting the cDNA using TdT (terminal deoxynucleotidyl transferase); 5) Biotinylating the cDNA fragments using the GeneChip WT Terminal labelling kit (Affymetrix); 6 Repeating steps 1 to 5 with a reference cell line, wherein said reference cell line is MDA-MB-231; 7) Hybridizing 5.5 μg of the biotinylated cDNA fragments obtained in step 5 to a Multiple Displacement Amplification:Article Title: Deoxy-cytidine or uridine derivatives for use in cancer therapies Article Snippet: .. Microarray Method A comprises the following steps: 1) Extracting RNA from cancer/tumour cells of interest, said extraction preferably being performed using a Norgen Total RNA Purification kit (Norgen Biotek Cat nr. 17200); 2) Preparing Poly(A)+ RNA from the extracted RNA, preferably using a MEGApure kit according to the manufacturer's instructions (Ambion); 3) Preparing complementary DNA (cDNA) from the Poly(A)+ RNA by treatment with reverse transcriptase, i.e. performing reverse transcription; 4) Fragmenting the cDNA using TdT (terminal deoxynucleotidyl transferase); 5) Biotinylating the cDNA fragments using the GeneChip WT Terminal labelling kit (Affymetrix); 6 Repeating steps 1 to 5 with a reference cell line, wherein said reference cell line is MDA-MB-231; 7) Hybridizing 5.5 μg of the biotinylated cDNA fragments obtained in step 5 to a Software:Article Title: Deoxy-cytidine or uridine derivatives for use in cancer therapies Article Snippet: .. Microarray Method A comprises the following steps: 1) Extracting RNA from cancer/tumour cells of interest, said extraction preferably being performed using a Norgen Total RNA Purification kit (Norgen Biotek Cat nr. 17200); 2) Preparing Poly(A)+ RNA from the extracted RNA, preferably using a MEGApure kit according to the manufacturer's instructions (Ambion); 3) Preparing complementary DNA (cDNA) from the Poly(A)+ RNA by treatment with reverse transcriptase, i.e. performing reverse transcription; 4) Fragmenting the cDNA using TdT (terminal deoxynucleotidyl transferase); 5) Biotinylating the cDNA fragments using the GeneChip WT Terminal labelling kit (Affymetrix); 6 Repeating steps 1 to 5 with a reference cell line, wherein said reference cell line is MDA-MB-231; 7) Hybridizing 5.5 μg of the biotinylated cDNA fragments obtained in step 5 to a Expressing:Article Title: Deoxy-cytidine or uridine derivatives for use in cancer therapies Article Snippet: .. Microarray Method A comprises the following steps: 1) Extracting RNA from cancer/tumour cells of interest, said extraction preferably being performed using a Norgen Total RNA Purification kit (Norgen Biotek Cat nr. 17200); 2) Preparing Poly(A)+ RNA from the extracted RNA, preferably using a MEGApure kit according to the manufacturer's instructions (Ambion); 3) Preparing complementary DNA (cDNA) from the Poly(A)+ RNA by treatment with reverse transcriptase, i.e. performing reverse transcription; 4) Fragmenting the cDNA using TdT (terminal deoxynucleotidyl transferase); 5) Biotinylating the cDNA fragments using the GeneChip WT Terminal labelling kit (Affymetrix); 6 Repeating steps 1 to 5 with a reference cell line, wherein said reference cell line is MDA-MB-231; 7) Hybridizing 5.5 μg of the biotinylated cDNA fragments obtained in step 5 to a |
